share_log

CORRESP: CORRESP

CORRESP: CORRESP

CORRESP：信函
美股sec公告 ·  04/12 13:23
Moomoo AI 已提取核心信息
Apollomics Inc., a biopharmaceutical company, has responded to a comment from the SEC regarding its operations in China. The SEC's Division of Corporation Finance had requested clarification on the extent of Apollomics' operations in China, as stated in their Registration Statement on Form F-3 filed on April 1, 2024. In a letter dated April 12, 2024, Apollomics clarified that the majority of its operations are not conducted in China but through its wholly-owned subsidiary in California, with its business headquarters and management team based in the United States. The company also highlighted that most of its research and development, including clinical trials, are conducted outside of China, particularly in the United States and Australia. Apollomics maintains that less than 20% of its R&D efforts and expenses are related to its operations in Hong Kong and mainland China, where it has two wholly-owned subsidiaries. The company further stated that the majority of its cash and expenditures are held and incurred outside of China, reinforcing that its primary operations are not China-centric.
Apollomics Inc., a biopharmaceutical company, has responded to a comment from the SEC regarding its operations in China. The SEC's Division of Corporation Finance had requested clarification on the extent of Apollomics' operations in China, as stated in their Registration Statement on Form F-3 filed on April 1, 2024. In a letter dated April 12, 2024, Apollomics clarified that the majority of its operations are not conducted in China but through its wholly-owned subsidiary in California, with its business headquarters and management team based in the United States. The company also highlighted that most of its research and development, including clinical trials, are conducted outside of China, particularly in the United States and Australia. Apollomics maintains that less than 20% of its R&D efforts and expenses are related to its operations in Hong Kong and mainland China, where it has two wholly-owned subsidiaries. The company further stated that the majority of its cash and expenditures are held and incurred outside of China, reinforcing that its primary operations are not China-centric.
生物制药公司Apollomics Inc. 对美国证券交易委员会关于其在中国业务的评论做出了回应。正如美国证券交易委员会于2024年4月1日提交的F-3表格注册声明中所述，美国证券交易委员会公司财务部已要求澄清Apollomics在中国的业务范围。在2024年4月12日的一封信中，Apollomics澄清说，其大部分业务不是在中国进行的，而是通过其位于加利福尼亚的全资子公司进行的，其业务总部和管理团队设在美国。该公司还强调，其大部分研发，包括临床试验，都是在中国境外进行的，特别是在美国和澳大利亚。Apollomics坚持认为，其研发工作和支出中只有不到20％与其在香港和中国大陆的业务有关，该公司在香港和中国大陆有两家全资子公司。该公司进一步表示，其大部分现金和支出都是在中国境外持有和产生的，这进一步表明其主要业务并不以中国为中心。
生物制药公司Apollomics Inc. 对美国证券交易委员会关于其在中国业务的评论做出了回应。正如美国证券交易委员会于2024年4月1日提交的F-3表格注册声明中所述，美国证券交易委员会公司财务部已要求澄清Apollomics在中国的业务范围。在2024年4月12日的一封信中，Apollomics澄清说，其大部分业务不是在中国进行的，而是通过其位于加利福尼亚的全资子公司进行的，其业务总部和管理团队设在美国。该公司还强调，其大部分研发，包括临床试验，都是在中国境外进行的，特别是在美国和澳大利亚。Apollomics坚持认为，其研发工作和支出中只有不到20％与其在香港和中国大陆的业务有关，该公司在香港和中国大陆有两家全资子公司。该公司进一步表示，其大部分现金和支出都是在中国境外持有和产生的，这进一步表明其主要业务并不以中国为中心。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息